Search details
1.
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Blood
; 133(16): 1742-1752, 2019 04 18.
Article
in English
| MEDLINE | ID: mdl-30803990
2.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med
; 371(20): 1877-88, 2014 Nov 13.
Article
in English
| MEDLINE | ID: mdl-25265492
3.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Lancet
; 386(9992): 444-51, 2015 Aug 01.
Article
in English
| MEDLINE | ID: mdl-26037941
4.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(8): 773-81, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22805291
5.
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(8): 782-9, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22805292
6.
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
EClinicalMedicine
; 62: 102131, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37599908
7.
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
EClinicalMedicine
; 63: 102130, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37662520
8.
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
Leuk Lymphoma
; 62(2): 368-376, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33140664
9.
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.
J Pharmacol Exp Ther
; 326(2): 432-42, 2008 Aug.
Article
in English
| MEDLINE | ID: mdl-18499743
10.
A Bni4-Glc7 phosphatase complex that recruits chitin synthase to the site of bud emergence.
Mol Biol Cell
; 14(1): 26-39, 2003 Jan.
Article
in English
| MEDLINE | ID: mdl-12529424
11.
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
Blood
; 113(19): 4819-20, 2009 May 07.
Article
in English
| MEDLINE | ID: mdl-19423744
12.
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.
Cancer Chemother Pharmacol
; 77(4): 807-17, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26940938
13.
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Eur J Cancer
; 51(7): 833-40, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25794603
14.
Intracellular hepatitis C virus RNA-dependent RNA polymerase activity.
J Virol Methods
; 113(1): 65-8, 2003 Oct.
Article
in English
| MEDLINE | ID: mdl-14500128
15.
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
J Clin Oncol
; 31(4): 482-9, 2013 Feb 01.
Article
in English
| MEDLINE | ID: mdl-23248257
16.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep
; 4(6): 1090-9, 2013 Sep 26.
Article
in English
| MEDLINE | ID: mdl-24055054
17.
Mutation of charged residues in the TR3 death domain does not perturb interaction with TRADD.
Protein Eng
; 15(10): 811-5, 2002 Oct.
Article
in English
| MEDLINE | ID: mdl-12468715
Results
1 -
17
de 17
1
Next >
>>